New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2 nd Annual Essentials in Primary Care<br />
Fall Conference<br />
Friday, November 11, <strong>2011</strong><br />
Dronedarone - Multaq<br />
<strong>New</strong> Safety Concern July 7, <strong>2011</strong> Paris, France<br />
Sanofi, maker of dronedarone (Multaq), has<br />
suspended its phase 3b trial of its<br />
antiarrhythmic drug due to a significant increase<br />
in cardiovascular events seen in patients<br />
randomized to dronedarone. The PALLAS trial<br />
(begun 7-<strong>2010</strong>) was testing the drug in ~10,000<br />
patients with permanent atrial fibrillation and at<br />
least one other cardiovascular disease risk<br />
factor; at present, dronedarone is approved in<br />
patients with nonpermanent AF.<br />
Events during the PALLAS study as of<br />
June 30, <strong>2011</strong>.(FDA MedWatch 7-21-<strong>2011</strong>)<br />
CV Death, Myocardial<br />
Infarction, Stroke, Systemic<br />
Embolism*<br />
Death, Unplanned CV<br />
Hospitalization*<br />
Multaq<br />
N=1572<br />
n (%)<br />
Placebo<br />
N=1577<br />
n (%)<br />
Hazard<br />
Ratio/NNH<br />
32 (2) 14 (0.9) 2.3/91 0.009<br />
118 (7.5) 81 (5.1) 1.5/42 0.006<br />
Death 16 (1) 7 (0.4) 2.3 0.065<br />
Myocardial Infarction 3 (0.2) 3 (0.2) 1.0 1<br />
Stroke 17 (1.1) 7 (0.4) 2.4/143 0.047<br />
Heart Failure Hospitalization 34 (2.2) 15 (1) 2.3/84 0.008<br />
*coprimary endpoints<br />
p-value<br />
Wayne Weart<br />
<strong>New</strong> <strong>Drug</strong> <strong>Update</strong> Part I